Molecular Challenges of Neuroendocrine Tumors

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Feb 20

PMID 29456718

Citations 9

Authors

Parthik Patel

Karina Galoian

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine tumors (NETs) are a very heterogeneous group that are thought to originate from the cells of the endocrine and nervous systems. These tumors develop in a number of organs, predominantly in the gastrointestinal and pulmonary systems. Clinical detection and diagnosis are reliable at the late stages when metastatic spread has occurred. However, traditional conventional therapies such as radiation and chemotherapy are not effective. In the majority of cases even surgical resection at that stage is unlikely to produce promising reusults. NETs present a serious clinical challenge, as the survival rates remain low, and as these rare tumors are very difficult to study, novel approaches and therapies are required. This review will highlight the important points of accumulated knowledge covering the molecular aspects of the role of neuroendocrine cells, hormonal peptides, the reasons for ectopic hormone production in NET, neuropeptides and epigenetic regulation as well as the other challenging questions that require further understanding.

Citing Articles

Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors.

Kenney L, Hughes M Cancers (Basel). 2025; 17(3).

PMID: 39941746 PMC: 11816225. DOI: 10.3390/cancers17030377.

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.

Grand-Guillaume J, Mansi R, Gaonkar R, Zanger S, Fani M, Eugster P J Transl Med. 2023; 21(1):604.

PMID: 37679770 PMC: 10485979. DOI: 10.1186/s12967-023-04466-z.

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice.

Lamarca A, Frizziero M, Barriuso J, Kapacee Z, Mansoor W, McNamara M Cancers (Basel). 2022; 14(4).

PMID: 35205766 PMC: 8870317. DOI: 10.3390/cancers14041017.

Evaluation of Gene Methylation in Neuroendocrine Neoplasms.

Della Monica R, Cuomo M, Visconti R, Di Mauro A, Buonaiuto M, Costabile D Oncol Res. 2021; 28(9):837-845.

PMID: 34016221 PMC: 8790131. DOI: 10.3727/096504021X16214197880808.

Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.

Mpilla G, Philip P, El-Rayes B, Azmi A World J Gastroenterol. 2020; 26(28):4036-4054.

PMID: 32821069 PMC: 7403797. DOI: 10.3748/wjg.v26.i28.4036.

References

Hochwald S, Zee S, Conlon K, Colleoni R, Louie O, Brennan M . Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002; 20(11):2633-42. DOI: 10.1200/JCO.2002.10.030. View

Heymann M, Joubert M, Nemeth J, Franc B, Visset J, Hamy A . Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology. 2000; 36(5):421-32. DOI: 10.1046/j.1365-2559.2000.00892.x. View

Baylin S, Mendelsohn G . Ectopic (inappropriate) hormone production by tumors: mechanisms involved and the biological and clinical implications. Endocr Rev. 1980; 1(1):45-77. DOI: 10.1210/edrv-1-1-45. View

Travis W, Rush W, Flieder D, Falk R, Fleming M, Gal A . Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998; 22(8):934-44. DOI: 10.1097/00000478-199808000-00003. View

Younes N, Fulton N, Tanaka R, Wayne J, Straus 2nd F, Kaplan E . The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer. 1997; 79(9):1804-8. View

Sippel R, Carpenter J, Kunnimalaiyaan M, Lagerholm S, Chen H . Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2003; 285(2):G245-54. DOI: 10.1152/ajpgi.00420.2002. View

Chan J, Kulke M . Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014; 15(3):365-79. PMC: 4147239. DOI: 10.1007/s11864-014-0294-4. View

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

Sauer C, Haugg A, Chteinberg E, Rennspiess D, Winnepenninckx V, Speel E . Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma. Crit Rev Oncol Hematol. 2017; 116:99-105. DOI: 10.1016/j.critrevonc.2017.05.009. View

10.

Shen M, Abate-Shen C . Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24(18):1967-2000. PMC: 2939361. DOI: 10.1101/gad.1965810. View

11.

Una Cidon E . New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol. 2017; 9(1):4-20. PMC: 5241526. DOI: 10.4251/wjgo.v9.i1.4. View

12.

Cueto A, Burigana F, Nicolini A, Lugnani F . Neuroendocrine tumors of the lung: hystological classification, diagnosis, traditional and new therapeutic approaches. Curr Med Chem. 2013; 21(9):1107-16. DOI: 10.2174/0929867321666131129125953. View

13.

Glikson M, Gil-ad I, Galun E, Dresner R, Zilberman S, Halperin Y . Acromegaly due to ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumour. Dynamic hormonal responses to various stimuli. Acta Endocrinol (Copenh). 1991; 125(4):366-71. DOI: 10.1530/acta.0.1250366. View

14.

Schindl M, Kaczirek K, Kaserer K, Niederle B . Is the new classification of neuroendocrine pancreatic tumors of clinical help?. World J Surg. 2000; 24(11):1312-8. DOI: 10.1007/s002680010217. View

15.

Li S, Essaghir A, Martijn C, Lloyd R, Demoulin J, Oberg K . Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol. 2013; 26(5):685-96. PMC: 3647117. DOI: 10.1038/modpathol.2012.216. View

16.

Stefanoli M, La Rosa S, Sahnane N, Romualdi C, Pastorino R, Marando A . Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors. Neuroendocrinology. 2014; 100(1):26-34. DOI: 10.1159/000365449. View

17.

Trobridge P, Knoblaugh S, Washington M, Munoz N, Tsuchiya K, Rojas A . TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology. 2009; 136(5):1680-8.e7. PMC: 2782436. DOI: 10.1053/j.gastro.2009.01.066. View

18.

Strosberg J, Cheema A, Weber J, Han G, Coppola D, Kvols L . Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011; 29(22):3044-9. DOI: 10.1200/JCO.2011.35.1817. View

19.

Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M . Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res. 1992; 52(18):5061-4. View

20.

Couderc C, Poncet G, Villaume K, Blanc M, Gadot N, Walter T . Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth. Am J Pathol. 2011; 178(1):336-44. PMC: 3069842. DOI: 10.1016/j.ajpath.2010.11.023. View